# ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice … – Lincoln Journal > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/envue-medical-adds-to-intellectual-property-portfolio-by-securing-uspto-notice-lincoln-journal/ > **Published:** 2026-05-08T17:06:41-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:55:48-04:00 > **Clinical Summary:** ENvue Medical patents ultrasound cannabinoid delivery technology. Clinical experts explain what patent allowance means for cannabis medicine practice. --- ✦ New CED Clinical Relevance #35 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. ResearchIndustryCBD Why This Matters This patent protection for surface acoustic wave ultrasound combined with cannabinoid delivery technology may enable clinicians to administer cannabis more precisely and predictably to patients, potentially reducing variability in dosing and therapeutic outcomes. The intellectual property portfolio securing this technology could accelerate clinical development and regulatory approval pathways for [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/), making evidence-based cannabinoid therapies more accessible to patients who might benefit from them. Clinicians should monitor this technology’s development as it could eventually provide an alternative delivery method with improved bioavailability and patient compliance compared to current cannabis administration routes. Clinical Summary ENvue Medical has secured additional intellectual property protection through USPTO approval of claims covering a combined surface acoustic wave (SAW) ultrasound and cannabinoid delivery system. This patent allowance expands the company’s IP portfolio and provides broad protection across multiple technological components of their novel delivery platform. Such innovations in cannabinoid delivery mechanisms are relevant to clinical practice as they may improve bioavailability, dosing precision, and therapeutic efficacy compared to conventional administration routes. For clinicians prescribing cannabis-based therapeutics, advancement in delivery technologies could eventually translate to more reliable pharmacokinetics and standardized dosing options. As cannabinoid delivery science matures through patented innovations and commercialization, clinicians should monitor emerging delivery systems that demonstrate superior efficacy or safety profiles in clinical studies. Clinicians interested in cannabis therapeutics should stay informed about advances in delivery technology that may eventually provide patients with more effective and predictable treatment options. Dr. Caplan’s Take “What matters clinically is whether this technology actually helps us deliver cannabinoids more precisely to patients who need them, not just whether the patent is broad. If ENvue’s ultrasound approach improves bioavailability or reduces systemic exposure for localized conditions, that’s meaningful, but we need the pharmacokinetic data to know if this is a real advance or intellectual property theater.” Clinical Perspective The intellectual property landscape around cannabis-based medical devices continues to evolve as companies develop novel delivery and monitoring technologies, as reflected in this patent for combined surface acoustic wave ultrasound and cannabinoid delivery systems. While such technological innovations may eventually enable more precise dosing, targeted delivery, or real-time monitoring of cannabinoid therapeuties, clinicians should remain cautious about extrapolating patent activity into near-term clinical utility or evidence of efficacy. The patent protection itself does not establish safety or effectiveness data, and the clinical relevance of these delivery mechanisms remains uncertain until rigorous pharmacokinetic and efficacy studies are completed. Given the ongoing gaps in standardization, dose-response relationships, and drug-drug interactions with cannabinoids, healthcare providers should continue to base cannabinoid recommendations on available clinical evidence rather than emerging technological capabilities. Staying informed about these developments may help clinicians contextualize patient inquiries about novel [cannabis therapies](https://cedclinic.com/deep-reading-decline-digital-age-insights/) while 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20ENvue%20Medical%20Adds%20to%20Intellectual%20Property%20Portfolio%20by%20Securing%20USPTO%20Notice%20...%20-%20Lincoln%20Journal%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D50884)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D50884)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20ENvue%20Medical%20Adds%20to%20Intellectual%20Property%20Portfolio%20by%20Securing%20USPTO%20Notice%20...%20-%20Lincoln%20Journal%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D50884)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.lincolnjournal.com/online_features/press_releases/envue-medical-adds-to-intellectual-property-portfolio-by-securing-uspto-notice-of-allowance-for-ultrasound/article_0dee1ca8-183f-5fb5-9d07-ef2fff41ea96.html](https://www.lincolnjournal.com/online_features/press_releases/envue-medical-adds-to-intellectual-property-portfolio-by-securing-uspto-notice-of-allowance-for-ultrasound/article_0dee1ca8-183f-5fb5-9d07-ef2fff41ea96.html) Further Reading Cannabis Policy Wire[Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://cedclinic.com/temporary-placement-bromazolam-schedule-i/) Research Digest[Research Digest: 20 Recent Studies – May 02, 2026](https://cedclinic.com/cannabinoid-based-interventions-autism-safety-effectiveness-2026/) CED Clinic BlogClinical trial finds no difference in fluid treatment options for pediatric sepsis [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).